Recent Publications by CFE Educators
Recent Published articles, books, and other scholarship by Academy members, CFE Education Scientists, and CFE Faculty.
See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
2022
Authors: Tasce Bongiovanni, Elizabeth Lancaster, Hannah Decker, Rita A. Mukhtar, Marisa Schwab, Jeanette Broering, Patricia O’Sullivan, Kenzo Hirose, Elizabeth Wick
Online Crowdfunding for Urologic Cancer Care.
2022
Authors: Rajwa P, Hopen P, Wojnarowicz J, Kaletka J, Paszkiewicz I, Lach-Wojnarowicz O, Mostafaei H, Krajewski W, D'Andrea D, Malkiewicz B, Paradysz A, Ploussard G, Moschini M, Breyer BN, Pradere B, Shariat SF, Leapman MS
SAGES safe cholecystectomy modules improve practicing surgeons' judgment: results of a randomized, controlled trial.
2022
Authors: Weis J, Brunt LM, Madani A, Telem D, Nagaraj M, Asbun H, Davis BR, Dissanaike S, Ujiki MB, Westcott CJ, Alseidi A, SAGES Safe Chole Task Force
Comprehensive Assessment of Clinical Learning Environments to Drive Improvement: Lessons Learned from a Pilot Program.
2022
Authors: Bernal J, Cresalia N, Fuller J, Gin B, Laves E, Lupton K, Malkina A, Marmor A, Wheeler D, Williams M, van Schaik S
ALSUntangled #65: glucocorticoid corticosteroids.
2022
Authors: Goslinga JA, Terrelonge M, Bedlack R, Barkhaus P, Barnes B, Bertorini T, Bromberg M, Carter G, Chen A, Crayle J, Dimachkie M, Jiang L, Levitsky G, Lund I, Martin S, Mcdermott C, Pattee G, Pierce K, Ratner D, Slachtova L, Sun Y, Wicks P
ALSUntangled reviews alternative and off-label treatments for people with amyotrophic lateral sclerosis (PALS). Here we review glucocorticoids. Neuroinflammation plays a prominent role in amyotrophic lateral sclerosis (ALS) pathogenesis, so some hypothesize that glucocorticoids might be an effective ALS therapy through their immunosuppressive effects. In this paper, we review the available evidence for glucocorticoids in ALS, including one pre-clinical study with a genetic mouse model of ALS, nine case reports (ranging from 1 to 26 patients each), and four clinical trials. We also review the possible side effects (including steroid myopathy) and the costs of therapy. We graded the level of evidence as follows: Mechanism, D; Pre-Clinical, F; Cases, B; Trials, F; Risks, C. Our review of the current evidence concludes that glucocorticoids do not offer clinical benefit in ALS and confer serious risks. Thus, ALSUntangled does not recommend glucocorticoids as a treatment for ALS.
View on PubMedLanguage barriers and postoperative opioid prescription use after total knee arthroplasty.
2022
Authors: Nguyen KH, Rambachan A, Ward DT, Manuel SP
The epidemiology of lung cancer following radiation exposure.
2022
Authors: Zablotska LB, Richardson DB, Golden A, Pasqual E, Smith B, Rage E, Demers PA, Do M, Fenske N, Deffner V, Kreuzer M, Samet J, Bertke S, Kelly-Reif K, Schubauer-Berigan MK, Tomasek L, Wiggins C, Laurier D, Apostoaei I, Thomas BA, Simon SL, Hoffman FO, Boice JD, Dauer LT, Howard SC, Cohen SS, Mumma MT, Ellis ED, Eckerman KF, Leggett RW, Pawel DJ
"It's All About the Trust And Building A Foundation:" Evaluation of a Longitudinal Medical Student Coaching Program.
2022
Authors: Hauer KE, Chang A, van Schaik SM, Lucey C, Cowell T, Teherani A
Assessing Technical Feasibility and Acceptability of Telehealth Palliative Care in Nursing Homes.
2022
Authors: Stephens CE, Allison TA, Flint LA, David D, Wertz V, Halifax E, Barrientos P, Ritchie CS
Liver allocation policies for hepatocellular carcinoma have leveled the playing field-But who should be playing?
2022
Authors: Kwong AJ, Mehta N
